Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma

Author:

Dai Jimin¹²,Huang Qichao³^ORCID,Niu Kunwei¹,Wang Bo¹,Li Yijie¹,Dai Chen⁴,Chen Zhinan⁵,Tao Kaishan¹^ORCID,Dai Jingyao¹⁵^ORCID

Affiliation:

1. Department of Hepatobiliary Surgery; The First Affiliated Hospital of Air Force Medical University; Xi'an China

2. The Cadet Team 6 (Regiment 6) of School of Basic Medicine; Air Force Medical University; Xi'an China

3. State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine; Air Force Medical University; Xi'an China

4. Department of Orthopedics; The First Affiliated Hospital of Air Force Medical University; Xi'an China

5. Department of Cell Biology, National Translational Science Center for Molecular Medicine; Air Force Medical University; Xi'an China

Funder

Science Foundation of Shaanxi Province

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

Reference64 articles.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献